Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience, Artisan Development Labs Collaborate on Antibody Discovery, Cell Therapies

NEW YORK – Twist Bioscience said on Tuesday that it is collaborating with Artisan Development Labs (Artisan Bio) to discover novel antibodies against five undisclosed targets.

Under the terms of the collaboration, Twist will apply its proprietary Library of Libraries to discover novel antibodies directed against Artisan Bio's immunotherapy targets. Artisan will leverage its Immune Cell Engineering Foundry and STAR Guides to develop custom cell therapeutics. Twist will receive upfront technology access and project fees for each program; success-based clinical, regulatory, and commercial milestones; and royalties on product sales.

The deal includes an option for additional targets. Other details were not disclosed.

"Artisan has a unique approach that combines a deep understanding of this gene-editing technology with advanced AI analysis," Twist cofounder and CEO Emily Leproust said in a statement. "Our collaboration with Artisan will leverage our innovative antibody discovery capabilities to help translate this cutting-edge approach into novel cell therapies."

Artisan Bio has operations in Denver; Copenhagen, Denmark; and Toronto. According to its website, it has received investment from XSeed Capital, Northpond Ventures, and Takeda Ventures.

Twist continues to build partnerships around antibody discovery. Last year it signed such deals with Pure Biologics, Adicet Bio, and Boehringer Ingelheim.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.